p53 in the clinics book

2013, 2013, VII, 544 p. 45 illus., Hardcover
ISBN 978-1-4614-3675-1
Table of contents
Ordering information

Edited by
Pierre Hainaut
International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France

Magali Olivier
International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France

Klas G. Wiman
Karolinska Institute, Dept. of Oncology-Pathology, Cancer Center Karolinska (CCK), Stockholm, Sweden

With over 60,000 referenced publications, p53 has emerged as one of the most important factors in human cancer. Research on p53 has led to a complete overhaul of our understanding of the molecular basis of human cancer. In recent years, these major advances in knowledge are starting to impact on cancer management and therapy. This book thus captures a critical turning point in p53 research, from basic to translational research and clinical application.

p53 in the Clinics follows the success of 25 Years of p53 Research and condensates in a series of authoritative chapters the considerable progress on the applications of p53 into the clinics and the substantial advances on diseases caused by inheritance of p53 defects, on somatic p53 mutations as biomarkers in molecular pathology, on progress in gene therapy and on developments of innovative drugs and clinical trials. This volume will appeal to a wide audience of students and professionals in basic and clinical cancer research and treatment, and will highlight the exciting “next steps” in p53 research and applications.

Table of contents

Chapter 1: TP53: Coordinator of the Processes That Underlie the Hallmarks of Cancer; Pierre Hainaut

Chapter 2: The inheritance of p53; Lukasz F. Grochola, Jorge Zeron-Medina, Emmanouela Repapi, Alexander E. Finlayson, Ying Cai, Gurinder Singh Atwal, and Gareth L. Bond

Chapter 3: p53: guardian of the metabolome; Masha V. Poyurovsky and Carol Prives

Chapter 4: The p53 family and stem cell biology; Massimiliano Agostini, Alessandro Rufini, Edward T.W. Bampton, Francesca Bernassola, Gerry Melino, and Richard A. Knight

Chapter 5: Mutant p53-driven tumorigenesis; Tamara Terzian and Guillermina Lozano

Chapter 6: Humanised Mouse Models: Targeting the Murine p53 Locus with Human Sequences; Monica Hollstein and Yang Xu

Chapter 7: p53 models for mammary carcinogenesis; Wolfgang Deppert and Genrich Tolstonog

Chapter 8: TP53 Somatic Mutations: Prognostic and Predictive Value in Human Cancers ; Magali Olivier

Chapter 9: Assessing TP53 status in human tumors: lessons from breast cancer; Anita Langerod, Magali Olivier, and Anne-Lise Borresen

Chapter 10: TP53 germline mutations: genetics of Li-Fraumeni Syndrome; Doua Bakry and David Malkin

Chapter 11: Tp53 Gene Therapy for Cancer Treatment and Prevention ; Robert E. Sobol, Yong-Song Guan, Long-Jiang Li, Wei-Wei Zhang, Zhaohui Peng, Kerstin B. Menander, Sunil Chada, Daniel C. Maneval, Jane A. Horowitz, Robert Warren, Gary L. Clayman, Stephen G. Swisher, W. Jarrod Goodman, John Nemunaitis, and Jack A. Roth

Chapter 12: Upstream targets in the p53 pathway; Anna R. McCarthy and Sonia Lain

Chapter 13: p53-Reactivating Molecules as Research Tools and Anticancer Drugs; Vera V. Grinkevich, Andreas Warnecke, and Galina Selivanova

Chapter 14: Targeting Mutant p53 for Improved Cancer Therapy ; Jinfeng Shen, Vladimir J.N. Bykov, and Klas G. Wiman

Chapter 15: p53-immunotherapy of cancer; Hakim Echchannaoui and Matthias Theobald

Chapter 16: Designing p53 trials: a surgical oncologists view; Daniela Kandioler, Sonja Kappel, and Brigitte Wolf

Chapter 17: p53 in the clinic: a pathologists view; Philippe Bertheau, Jean-François Fléjou, Yves Allory, Pascale Varlet, Sylvie Lantuejoul, Louis-François Plassa, Hugues de Thé, Anne Janin, and Jacqueline Lehmann-Che

Chapter 18: Genetic Counseling for TP53 germline mutations; Maria Isabel Waddington Achatz and Patricia Ashton-Prolla